Mastering Radiopharmaceutical Development - Preclinical Model Selection for Clinical Success

In this CrownCast episode, host Michelle Dawn Mooney speaks with Graham Marsh, Director of the NAMs Developer Coalition at the Critical Path Institute, and Ludovic Bourré, Vice President of Research and Innovation at Crown Bioscience, to explore new approach methodologies (NAMs) and Crown Bioscience’s participation in the coalition. Together, they discuss how patient-derived models, organoids, ex vivo tissue platforms, translational biomarkers, and bioinformatics contribute to the field, and what validation, qualification, and regulatory adoption could mean for practical study design.

Choosing the right preclinical immuno-oncology model makes or breaks your development decisions, but navigating the options is rarely simple. In this CrownCast episode, host Michelle Dawn Mooney sits down with Chris Dillon, Executive Director of In Vivo at Crown Bioscience's San Diego site, to explore how syngeneic tumor models support preclinical immunotherapy research and how model selection, engineering, and translational relevance come together to build studies that deliver actionable results.

At AACR 2026, one message became clear: oncology drug development is entering a new era defined by smarter decision-making, integrated platforms, and increasingly precise therapeutic strategies. In this CrownCast episode, Crown Bioscience experts shared their perspectives from the conference, highlighting the technologies, modalities, and translational approaches that are poised to shape the future of cancer research. From AI-enabled target discovery to spatial biology and next-generation therapeutic modalities, the discussions reflected a rapidly evolving ecosystem where innovation is no longer incremental. Instead, the industry is moving toward highly integrated workflows designed to accelerate development timelines, reduce risk, and improve patient outcomes.

What if the next breakthrough in cancer treatment isn't a pill or infusion, but a precisely targeted radioactive payload that hunts down tumor cells like a guided missile? In this Smart Biotech Scientist Podcast episode, Dr. David Brühlmann speaks with Bryan Miller, Director of Scientific and Technical Operations at Crown Bioscience UK, about the radiopharmaceutical revolution transforming oncology. From theranostic approaches to advanced preclinical modeling, Miller shares insights on how this emerging therapeutic class is reshaping cancer treatment strategies.

When people hear Crown Bioscience, they often think of world-class in vivo oncology models - and for good reason. But behind every successful oncology program is something just as critical: understanding how a drug behaves in the body and whether it can do so safely. In this CrownCast episode, host Michelle Dawn Mooney sits down with Rekha Pal, Senior Director of Scientific Engagement, and Santi Suryani Chen, Director of Business Development at Crown Bioscience, to explore where DMPK and toxicology fit into the drug discovery picture and how getting them right can save programs from costly detours.

Across the global oncology drug discovery landscape, the UK stands at the forefront. In this CrownCast episode, Rajendra Kumari, Executive Director of Integrated Solutions at Crown Bioscience, talks with Sarah Wagner, Senior Director of Business Development and Bryan Miller, Director of Scientific and Technical Operations about leveraging the UK’s vibrant ecosystem of cutting-edge technologies, strong collaborations, and a commitment to high ethical standards.

What if the biggest barrier to faster, safer drug development isn't a lack of technology, but a decades-old reliance on the wrong models? In this episode of CrownCast, host Michelle Dawn Mooney sits down with Prof. Thomas Hartung, member of Crown Bioscience's Scientific Advisory Board and Director of the Johns Hopkins Center for Alternatives to Animal Testing, to unpack how the FDA Modernization Act, AI, and next-generation in vitro systems are transforming drug discovery. Watch or listen to the full conversation below.

Oncology continues to be a rapidly changing field with scientific discoveries transforming patient treatment and care. As it stands today, advancements in biomarkers are playing a vital role in furthering drug development and personalized medical approaches. In this episode of CrownCast, host Michelle Dawn Mooney interviews Julie Mayer, Vice President of Crown Bioscience's Global Biomarker Platform, regarding the critical role of biomarkers in oncology and drug development. Julie discusses the importance of implementing biomarker strategies early in the development pipeline, covering aspects such as target identification, patient selection, and companion diagnostics.